:::

詳目顯示

回上一頁
題名:專利連結之歷史、緣由及其政策功能
書刊名:智慧財產權月刊
作者:張哲倫
作者(外文):Chang Roger
出版日期:2015
卷期:196
頁次:頁5-19
主題關鍵詞:專利連結Hatch-Waxman試驗免責藥品查驗專利期間延長
原始連結:連回原系統網址new window
相關次數:
  • 被引用次數被引用次數:期刊(7) 博士論文(0) 專書(0) 專書論文(0)
  • 排除自我引用排除自我引用:6
  • 共同引用共同引用:24
  • 點閱點閱:2
專利制度或提供專利權保障之目的,本身僅係一種政策工具(policy tool),其真正目的在於提供誘因以獎勵發明,達成促進經濟成長之目的。Hatch-Waxman Act法案的正式全稱,本含有藥價競爭(drug price competition)之本意,法案簡化學名藥之申請流程、強化新藥專利權之保護,形式上觀之,簡化ANDA或專利期間延長,或對學名藥廠有利,或對原廠有利,然這些立法舉措,純為手段, Hatch-Waxman Act最上位之政策目的,在於以促進雙方競爭為手段,並以追求市場上同時有價廉之學名藥及物美之新藥,以服務消費者,最終以消費者之利益——得同時享受價廉學名藥及質優原廠藥為目的,此方為Hatch-Waxman Act法案或專利連結之最上位概念。
期刊論文
1.李素華(20120600)。醫藥發明之專利個案探討:以我國長青樹藥品專利為例。國立臺灣大學法學論叢,41(2),647-723。new window  延伸查詢new window
2.黃慧嫺(20090200)。專利連結(Patent Linkage)--藥品研發與競爭之阻力或助力?:談藥品查驗登記程序與專利權利狀態連結之發展。科技法律透析,21(2),24-37。  延伸查詢new window
3.Grossman, Steven J.(1990)。Experimental Use or Fair Use as a Defense to Patent Infringement。IDEA,30,243。  new window
4.Hantman, Rolland D.(1985)。Experimental Use as an Exception to Patent Infringement。Journal of the Patent and Trademark Office Society,67,617。  new window
5.Eisenberg, Rebecca S.(1989)。Patents and the Progress of Science: Exclusive Rights and Experimental Use。The University of Chicago Law Review,56(3),1017-1086。  new window
6.王立達(20080100)。限制競爭之專利侵害和解:尋求合適分析架構。全國律師,12(1),51-62。  延伸查詢new window
7.Eisenberg, Rebecca S.(1987)。Proprietary Rights and the Norms of Science in Biotechnology Research。Yale Law Journal,97(2),177-231。  new window
8.Mossinghoff, Gerald J.(1999)。Overview Of The Hatch-Waxman Act And Its Impact On The Drug Development Process。Food and Drug Law Journal,54(2),187-194。  new window
9.Mueller, Janice M.(2001)。No "Dilettante Affair": Rethinking The Experimental Use Exception To Patent Infringement For Biomedical Research Tools。Washington Law Review,76(1),1-65。  new window
10.Kieff, F. Scott(2001)。Property Rights and Property Rules for Commercializing Inventions。Minnesota Law Review,85,697-754。  new window
11.Merrill, Richard A.(1996)。The Architecture of Government Regulation of Medical Products。Va. L. Rev.,82,1753+1761-1766。  new window
12.Weiswasser, Elizabeth Stotland、Danzis, Scott D.(2003)。The Hatch-Waxman Act: History, Structure, and Legacy。Antitrust Law Journal,71(2),585-608。  new window
13.李素華、張哲倫(20131200)。專利審查品質與專利訴訟的實證考察--臺灣智慧財產法院成立五年的數據回顧。月旦裁判時報,24,94-112。  延伸查詢new window
14.Robinson, Laura J.(2003)。Analysis of Recent Proposals to Reconfigure Hatch-Waxman。Journal of Intellectual Property Law,11,47-52。  new window
15.ENGELBERG, ALFRED B.(1999)。SPECIAL PATENT PROVISIONS FOR PHARMACEUTICALS: HAVE THEY OUTLIVED THEIR USEFULNESS? A POLITICAL, LEGISLATIVE AND LEGAL HISTORY OF U.S. LAW AND OBSERVATIONS FOR THE FUTURE。IDEA,39,389-428。  new window
16.Flannery, Ellen、Hutt, Peter(1985)。Balancing Competition and Patent Protection in the Drug Industry: The Drug Price Competition and Patent Term Restoration Act of 1984。Food, Drug, Cosmetic Law Journal,40(3),269-309。  new window
17.Behrendt, Kristin E.(2002)。The Hatch-Waxman Act: Balancing Competing Interests or Survival of the Fittest?。Food Drug L. J.,57,247-249。  new window
18.Israelsen, Ned A.(1989)。Making, Using, and Selling Without Infringing: An Examination of 35 U.S.C. Section 271(e) and the Experimental Use Exception to Patent Infringement。AIPLA Q. J,16,457。  new window
19.Michel, Suzanne T.(1992)。The Experimental Use Exception to Infringement Applied to Federally Funded Inventions。High Tech. L. J,7,369。  new window
20.Grom, Taren(19991001)。GENERICS Best Years to Come。MED AD NEWS。  new window
21.Solow, Robert Merton(1957)。Technical Change and the Aggregate Production Function。The Review of Economics and Statistics,39(3),312-320。  new window
22.黃慧嫺(20060600)。淺析美國藥品上市審查程序之專利連結機制及其實施對我國可能產生之影響。科技法律透析,18(6),2-7。  延伸查詢new window
23.王立達、陳蔚奇(20101200)。學名藥上市審查之專利連結制度:從美國經驗檢證其存立基礎與制度設計。國立臺灣大學法學論叢,39(4),349-406。new window  延伸查詢new window
24.Karp, Jordan P.(1991)。Note: Experimental Use as Patent Infringement: The Impropriety of a Broad Exception。The Yale Law Journal,100,2169-2188。  new window
會議論文
1.(1982)。Patent Term Extension and Pharmaceutical Innovation: Hearing on H. R. 1937 Before the Subcomm. On Investigations and Oversight of the Committee。Science and Technology, 97th Congress。  new window
研究報告
1.(2014)。103年度『國際藥事與產業經貿法規政策對我國藥事法規修訂之研究計畫』。  延伸查詢new window
2.(2014)。美國專利連結與橘皮書登錄制度研究。  延伸查詢new window
學位論文
1.李素華(2006)。從公共衛生之觀點論醫藥專利權之保護與限制(博士論文)。臺灣大學。new window  延伸查詢new window
2.陳蔚奇(2010)。論美國專利連結制度於我國實行之妥適性(碩士論文)。國立交通大學。  延伸查詢new window
3.廖柏豪(2013)。論專利連結與資料保護對我國醫藥產業之影響(碩士論文)。國立臺北大學。  延伸查詢new window
4.蘇建智(2004)。藥品查驗登記制度與智慧財產權保護(碩士論文)。東吳大學。  延伸查詢new window
圖書
1.Bessen, James、Meurer, Michael J.(2008)。Patent Failure: How Judges, Bureaucrats, and Lawyers Put Innovators at Risk。Princeton University Press。  new window
2.Burk, Dan L.、Lemley, Mark A.(2009)。The Patent Crisis and How the Courts Can Solve It。  new window
單篇論文
1.Congressional Budget Office, The congress of the United States(1998)。How increased competition from generic drugs has affected prices and returns in the pharmaceutical industry,http://www.cbo.gov/showdoc.cfm?index=655&sequence=0&from=1。  new window
其他
1.Federal Trade Commission(2002)。Generic Drug Entry Prior to Patent Expiration: An FTC Study,http://www.ftc.gov/os/2002/07/genericdrugstudy.pdf, 。  new window
2.祈若鳳,潘香櫻(2007)。赴美國研習專利連結及橘皮書相關配套之運作及參加美國聯邦食品藥物管理局(FDA)舉辦之『國際藥品主管機關論壇』會議出國報告。  延伸查詢new window
3.吳佳穎,喬建中(2007)。美國醫藥專利連結制度研習報告。  延伸查詢new window
4.(19840625)。Much Haven for Drug Pioneers?。  new window
5.TUFTS CENTER FOR THE STUDY OF DRUG DEVELOPMENT(2001)。BACKGROUNDER: A METHODOLOGY FOR COUNTING COSTS FOR PHARMACEUTICAL R&D,http://csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=5。  new window
6.Stolberg, Sheryl Gay,Gerth, Jeff(20000723)。How Companies Stall Generics and Keep Themselves Healthy。  new window
圖書論文
1.陳昭華、鐘鏡湖、張乃文、鄭耀誠(2010)。新藥監視期、資料專屬及專利連結制度對學名藥上市之影響。基因體醫學研發創新與智慧財產權。  延伸查詢new window
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top
:::
QR Code
QRCODE